Research Progress on Small-molecule Compounds  against Connective Tissue Growth Factor

Abstract

Abstract: Objective To provide a concise overview of small molecule connective tissue growth factor (CTGF) inhibitors. Methods A summarization of the small molecules was provided, both the approved drugs and the agents under developing with new structures, that can inhibit CTGF. Results The research on small molecule CTGF inhibitors could be mainly classified into two categories: one is based on the approved drugs or natural products, the other is the small molecule compounds with new structures. Conclusion As a very important cytokine which is only expressed in interstitial cells, CTGF, inducing the fibrosis of TGF-β, is an effective and specific target for anti-fibrosis cytokine in organism. There are only a few structural types of compounds reported, but they will also be the prelude to provide useful references for developing more potential small molecule CTGF inhibitors in the future.

Key words: connective tissue growth factor, tissue fibrosis, small-molecule compound

CLC Number:

R965

LIU Jun-li, ZHANG Mu-xin, LIANG Di, ZHENG Ming-xin, ZHOU Xiao-ping. Research Progress on Small-molecule Compounds against Connective Tissue Growth Factor[J]. Chinese Journal of Pharmacovigilance, 2018, 15(2): 98-102.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2018/V15/I2/98

References

[1] Bradham D M, Igarashi A, Potter R L. Connective tissue growth factor: a cystine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10[J]. J Cell Biol, 1991, 114(6): 1285-1294.
[2] Moussad E E, Brigstock D R. Connective tissue growth factor: what's in a name?[J]. Mol Genet Metab, 2000, 71(1/2): 276-292.
[3] Gressner O A, Gressner A M. Connective tissue growth factor: a fibrogenic master swith in fibrotic liver diseases[J]. Liver International, 2008, 28(8): 1065-1079.
[4] Melennan S V, Abdollahi M, Twigg S M. Connective tissue growth factor, matrix regulation, and diabetic kidney disease[J]. Curr Opin Nephrol Hyperten, 2013, 22(1): 85-92.
[5] Shi-Wen X, Leask A, Abramham D J. Regulation and function of connectivetissuegrowth factor/CCN2 intissue repair, scarring and fibrosis[J]. Cytokine & Growth Factor Reviews, 2008, 19(2): 133-144.
[6] Ahmad A, Ahmad R. Understanding the mechanism of hepaticfibrosis and potential therapeutic approaches[J]. Saudi J Gastroenterol, 2012, 18(3): 155-167.
[7] Gao R, Brigstock D R. Low density lipoprotein receptor-relatedprotein (LRP) is a heparin-dependent adhesion receptor for conn-ectivetissue growth factor (CTGF) in rat activated hepatic stellate cells [J].Hepatol Res, 2003, 27(3): 214-220.
[8] Ozaki S, Sato Y, Yasoshima M, et al. Diffuseexpression of heparan sulfate proteoglycan and connective tissuegrowth factor in fibrous septa with many mast cells relate tounresolving hepatic fibrosis of congenital hepatic fibrosis [J]. LiverInternational, 2005,25(4): 817-828.
[9] Yang M, Huang H, Li J, et al. Tyrosine phosphorylation of the LDL receptor-related(LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation [J]. FASEB J, 2004,18(15): 1920-1921.
[10] Huang G, Brigstock D R, Integrin expression and function in the response of primary culture hepatic stellate cells to connective tissue growth factor(CCN2) [J]. Journal of cellular and molecular medicine, 2011,15(5): 1087-1095.
[11] Chen Y, Segarini P, Raoufi F, et al. Connective tissue growth factor is secreted through the Golgi and is degraded in the endosome[J]. Exp Cell Res, 2001,271(1): 109-177.
[12] Chen M M, Lam A, Abraham J A, et al.CTGFexpression is induced by TGF-beta in cardiac fibroblastsand cardiac my ocytes:a potential role in heart fibrosis[J].J Mol Cell Cardiol, 2000, 32(10):1805-1819.
[13] Piao R L, Brigstock D R, Zhu J, et al. Clinical significanceof connective tissue growth factor in hepatitis B virus－inducedhepatic fibrosis[J]. World J Gastroenterol, 2012, 18(18): 2280-2286.
[14] Julia R, Louis P S, Gerhard E, et al. 4-Dechloro-14-deoxy-oxacyclododecindione and 14-deoxy-oxacylododecindione, two inhibitors of inducibleconnective tissue growth factor expression from the imperfect fungus Exserohilum rostratum[J]. Bioorangic & Midicinal Chemistry, 2015, 23(3): 556-563.
[15] Gerhard E, Hanane B, Annegret S, et al. Oxacyclododecidione, a novel inhibitor of IL-4 signaling from Exserohilum rostratum[J]. Antibiotics, 2008, 61(5): 285-290.
[16] Kim K H, Park G T, Lim Y P, et al. Expression of connective tissue growth factor, a biomarkerin senescence of human diploid fibroblasts, is up-regulated bya transforming growth factor-β-mediated signaling pathway[J]. Biochemical and Biophysical Research Communications, 2004, 318(4): 819-825.
[17] Allen S, Andrews S W, Baer B, et al. 1-((3S, 4R)-4-(3-fluorophenyl)-1-(2-metho- xyethyl)pyrrolidin-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor: WO, 2015175788 A1[P]. 2015-11-19.
[18] Seno K, Shinosaki T. CTGF expression inhibitor: EP, 1839655 A1 [P]. 2007-10-03.
[19] 冯彦华,肖莉, 万宏光, 等. 辛伐他汀对肺纤维化大鼠肺内结缔组织生长因子表达的影响[J]. 中国医科大学学报, 2010, 39(9): 719-723.
[20] Watts K L, Sampson E M, Schultz G S, et al. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts [J]. Am J Respir Cell Mol Biol, 2005, 32(4): 290-300.
[21] Tan A, Levrey H, Dahm C, et al. Lovastatin induces Fibroblast Apoptosis In Vitro and In Vivo: A Possible Therapy for Fibroproliferative Disorders[J]. Am J Respair Crit Care Med, 1999, 159(1): 220-227.
[22] Oh Y. Methods and compositions for treatment of tumor metastasis: US, 20120156216 A1 [P]. 2012-06-21.
[23] Hitoshi Y, Shigeki K, Ryuichi N, et al. Angiotensin-II and vascular endothelial growth factor interaction plays an imporment role in rat liver fibrosis development[J]. Hepatology Research, 2006, 36(2): 124-129.
[24] 黄颂敏, 刘芳, 刘小菁,等. 血管紧张素Ⅱ及其受体拮抗剂在系膜细胞培养中对结缔组织生长因子表达的影响[J]. 肾脏病与透析肾移植杂志, 2000, 9(5): 420-423.
[25] 姜美华, 徐友平, 姚国乾,等. 缬沙坦对心肌成纤维细胞转化生长因子和结缔组织生长因子表达的影响[J]. 西部医学, 2013, 25(4): 493-497.
[26] 王文丽, 李孝生, 陈爽. 川芎嗪对肝星状细胞增殖及结缔组织生长因子表达的影响[J]. 中国生物制品学杂志, 2009, 22(1): 65-68.
[27] Hu J, Cao G, Wu X, et al. Tetramethylpyrazine Inhibits Activation of Hepatic Stellate Cellsthrough Hedgehog Signaling Pathways In Vitro [J]. BioMedResearch International, 2015: 603067/1-603061/6.
[28] Liang B, Guo X L, Jin J, et al. Glycyrrhizic acidinhibits apoptosis and fibrosis in carbon-tetrachloride-inducedrat liver injury[J]. World J Gastroenterol, 2015, 21(17): 5271-5280.
[29] Zheng S Z, Chen A. Curcumin suppresses the expression of extracellular matrix genes in activatedhepatic stellate cells by inhibiting gene expression of connectivetissue growth factor[J]. American Journal of Physiology, 2006, 290(5): G883-G893.
[30] Chen S R, Zhang W P, Bao J M, et al. Aristoyunnolin H attenuates extracellular matrix secretionin cardiac fibroblasts by inhibiting calcium influx [J]. Arch. Pharm. Res., 2017, 40(1): 122-130.

Research Progress on Small-molecule Compounds against Connective Tissue Growth Factor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[2]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[3]	DENG Baoyi, LI Yanning, ZHOU Liu, ZHANG Guozhuang, CAO Chunyu, LI Chun, ZHAO Chunhui, YANG Yifei, LIU Ting, ZHANG Haijing. Regulation of hERG Channels by Hypaconitine and Its Cardiotoxicity [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 763-770.
[4]	CUI Mengyao, LI Shuran, XIE Dan, YANG Xiaowei, LIU Xian, CUI Xiaolan, GENG Zihan, GUO Shanshan. Research Progress in Antiviral Targets and Active Ingredients of Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 481-487.
[5]	ZHAO Ronghua, ZHU Chunxu, SUN Jing, BAO Lei, WANG Xinwei, GENG Zihan, ZHANG Jingsheng, GUO Shanshan, LI Shuran, WANG Daohan, CUI Xiaolan. Mechanisms of Sanhan Huashi Granules on a Respiratory Syncytial Virus and Influenza Virus and Respiratory Syncytial Virus Induced Pneumonia Model in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 488-494.
[6]	LIU Xian, ZHANG Yu, BAI Yinglu, CUI Mengyao, YANG Xiaowei, XIE Dan, GENG Zihan, SUN Jing, LI Shuran, BAO Lei, ZHAO Ronghua, XU Xiaolong, GUO Shanshan. Potential Targets and Components of Jinhua Qinggan Granules against Respiratory Viral Infections [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 501-506.
[7]	CAO Weiping, ZHANG Shichao, NI Xia, XIE Bing, WANG Xinzhi, XING Mengtao. Research Progress in Liver Injury Caused by Drugs Commonly Used during Pregnancy [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 528-531.
[8]	ZHANG Huiting, LI Youlin, LI Lei, YAN Yue, YAO Ting, LI Chunlei, SHI Qi. Toxicity of Single-Dose and Repeated-Dose Administration of Guisha Zichuan Granules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 547-553.
[9]	LI Shuran, XIE Rui, ZHAO Ronghua, BAO Lei, GENG Zihan, SUN Qiyue, CUI Xiaolan, GUO Shanshan, SUN Jing. Research Progress in the Pathogenesis and Medications of Trigeminal Neuralgia [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 596-600.
[10]	KANG Jiaqi, GUO Xiaofei, SU Hongmei, BAI Jianqi, ZHU Hongwei, BAI Xin, CHEN Xin, WANG Hao, ZHAO Xiaoqi, GUO Dongqi, WANG Yuan, ZHANG Ping. Interventions of Bushen Huoxue Decoction in Lumbar Intervertebral Disc Degeneration of Kidney Deficiency and Blood Stasis Type in Rats [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 249-257.
[11]	BAI Xin, WANG Min, WANG Yuan, BAI Jianqi, SU Shuang, LIU Guanghui, GUO Xiaofei, KANG Jiaqi, GUO Dongqi, ZHANG Yimeng, WANG Hao, ZHAO Xiaoqi, ZHANG Ping. Traditional Chinese Medicine Used in the Treatment of Gout Complicated with Osteoarthritis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 258-262.
[12]	TANG Qianhui, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou. Research Progress in Triptolide-Induced Live Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 121-127.
[13]	TANG Qianhui, ZHU Ying, ZHANG Haoran, ZHANG Luyong, JIANG Zhenzhou. Roles of Hepatocellular NF-κB Signaling Pathway in Triptolide-Induced Indirect Liver Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 128-138.
[14]	JIA Juanjuan, SUN Jiabei, ZHANG Wenzai, SUN Deyang, SHI Yaqin, HUANG Haiwei. Biological Distribution of ^99mTc-DMSA Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 47-52.
[15]	HOU Tiantian, WANG Xudong, YANG Ping, ZHOU Pengbo, QIN Chao, HUANG Ying, WANG Ailing, GENG Xingchao, ZHOU Xiaobing, LIU Defang. Biodistribution of Therapeutic DNA Vaccines in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 58-66.